Agilent Acquires Seahorse Bioscience

This week, Agilent finalized its acquisition of Seahorse Bioscience, an industry leader in cellular metabolism (the study of chemical processes that occur within a cell).

The ability to see what is going on inside of a cell is tremendously important.  Scientists researching aging, obesity, diabetes, cancer, cardiovascular, neurodegeneration and many other diseases need to know how a cell’s functions are affected by potential drugs.

Seahorse offers a revolutionary and groundbreaking technology: it can measure a cell’s bioenergetic functions in real time.  Researchers can profile the metabolic activity of a living cell as it is happening.  And they can do so non-invasively, without disturbing the cell itself.

Since its introduction in 2006, Seahorse XF Technology has been featured in more than 2,000 peer-reviewed published research papers.  It is currently used by nearly 10,000 scientists around the world.

XF Technology simultaneously measures two major energy-producing pathways of the cell: mitochondrial respiration and glycolysis.  (XF stands for “extracellular flux.”)  Because XF measurements are non-destructive, the metabolic rate of the same cell population can be measured repeatedly over time, while up to four different drugs can be injected sequentially.

“Seahorse Bioscience’s unique technology is the perfect complement to Agilent, in particular for metabolomics research and disease research,” says Agilent’s Patrick Kaltenbach.  “This combination gives scientists a more comprehensive and faster path to researching the most challenging diseases facing mankind.”


For more information go to: